Eli Lilly and Incyte announce results from its phase 3 study evaluating baricitinib 2 mg and 4 mg for the treatment of alopecia areata, making it the first Phase 3 study with top-line results in patients with the hair disorder.
The AAD announced it will begin accepting applications soon for its 2021 Hair Loss and Alopecia Initiative in Research (HAIR) Grant Program, which focuses on helping fund research for hair disorders, especially in diverse populations.
Trichometric analysis helps evaluate whether treatment is working for patients experiencing hair loss and what adjustments need to be made to the regimen.